Gavi to use restored US funds for malaria vaccines
The global vaccine group Gavi intends to use 600 million dollars in restored U.S. funding to bolster malaria vaccination efforts in sub-Saharan Africa. The organization will also meet U.S. conditions to phase out the preservative thimerosal by transitioning to newer meningitis and hexavalent vaccines.
Gavi plans to deploy $600 million in restored United States funding to expand malaria vaccination programs and other immunization efforts. The capital injection follows a year-long freeze and addresses a projected $1.9 billion budget shortfall for the 2026–2030 period. Restoring these funds supports preventive campaigns for diseases like cholera and accelerates a transition to mercury-free formulas requested by U.S. health officials.
